<DOC>
	<DOCNO>NCT00236990</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness ELMIRONÂ® treatment chronic non-bacterial inflammation prostate gland .</brief_summary>
	<brief_title>An Effectiveness Safety Study ELMIRON ( Pentosan Polysulfate Sodium ) Treatment Chronic Non-Bacterial Inflammation Prostate Gland</brief_title>
	<detailed_description>The objective randomized , double-blind , placebo-controlled study determine effectiveness safety ELMIRON® 100 mg three time per day 12 week , compare placebo , patient chronic non-bacterial inflammation prostate gland . Safety evaluation assess throughout study . The hypothesis study ELMIRON® effective placebo , base change total National Institutes Health Chronic Prostatitis Symptom Index ( NIH-CPSI ) score baseline final visit ( Week 12 ) generally well-tolerated . Patients receive oral ELMIRON® 100 mg three time per day orally match placebo three time per day 12 week .</detailed_description>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Pentosan Sulfuric Polyester</mesh_term>
	<criteria>Diagnosis chronic nonbacterial prostatitis/chronic pelvic pain syndrome symptom discomfort pain perineal and/or pelvic region ( low abdomen ) least three last six month recognize cause symptom persist despite treatment antibiotic nonbacterial prostatitis past six month . Clinically significant medical problem organ abnormality psychiatric disorder urinary tract infection last three month history bladder , urethral prostate cancer Prostate Specific Antigen ( PSA ) great equal 4 ng/mL diagnosis treatment genital herpes herpes flare within last year .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>prostatitis</keyword>
	<keyword>Elmiron</keyword>
	<keyword>pentosan polysulfate sodium</keyword>
</DOC>